These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11975834)

  • 21. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Gavras I; Gavras H
    Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
    Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
    Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
    Elliott WJ
    J Hum Hypertens; 1999 Jun; 13(6):413-7. PubMed ID: 10408592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eprosartan for the treatment of hypertension.
    Ruilope L; Jäger B
    Expert Opin Pharmacother; 2003 Jan; 4(1):107-14. PubMed ID: 12517247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs of eprosartan versus diuretics for treatment of hypertension in a geriatric population: an observational, open-label, multicentre study.
    Gregori JA; Nuñez JF; Domínguez-Gil A;
    Drugs Aging; 2009; 26(7):617-26. PubMed ID: 19655828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
    Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
    Sega R
    Blood Press; 1999; 8(2):114-21. PubMed ID: 10451039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of eprosartan.
    Gavras I; Gavras H
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):102S-107S. PubMed ID: 10213529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
    Rake EC; Breeze E; Fletcher AE
    J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
    Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
    Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
    Martin DE; DeCherney GS; Ilson BE; Jones BA; Boike SC; Freed MI; Jorkasky DK
    J Clin Pharmacol; 1997 Feb; 37(2):155-9. PubMed ID: 9055142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
    Argenziano L; Trimarco B
    Curr Med Res Opin; 1999; 15(1):9-14. PubMed ID: 10216806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
    Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
    Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
    Conter HS; McKay DW; Reiz RJ
    Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.